Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the mainstream route of drug administration to the posterior segment of the eye. The purpose of this review is to assess the current literature about the widening use of the intravitreal 0.7 mg dexamethasone (Dex) implant, and to provide a comprehensive collection of all the ocular disorders that benefit from Dex administration. Although anti-vascular endothelial growth-factors (VEGFs) have been largely indicated as a first-choice level, the Dex implant represents an important treatment option, especially in selected cases, such as vitrectomized eyes or patients in whom anti-VEGF failed or are contraindicated. In this article, the safety profile as well as the list of the possible complications related to intravitreal Dex injection are also discussed.

中文翻译：

---

玻璃体内地塞米松植入物作为治疗眼部疾病的缓释药物输送装置：文献综述。

由于眼睛的复杂解剖结构和生理学，将药物输送到玻璃体腔在制药行业仍然是一个巨大的挑战。玻璃体内注射是向眼后段给药的主流途径。这篇综述的目的是评估有关玻璃体内0.7 mg地塞米松（Dex）植入物的广泛使用的当前文献，并提供受益于Dex给药的所有眼部疾病的全面收集。尽管抗血管内皮生长因子（VEGF）已被广泛认为是首选水平，但Dex植入物是重要的治疗选择，尤其是在某些情况下，例如玻璃体切除的眼睛或抗VEGF失败或禁忌。在这篇文章中，